EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Genmab outlined plans to increase its spending by as much as 45% in 2020. The anticipated surge in operating expenses reflects Genmab’s plans for development of its CD3xCD20 and PD-L1x4-1BB bispecifics. Annual report

> Montis Biosciences raised €8.4 million ($9.1 million) to advance immuno-oncology treatments for solid tumors. Pfizer Ventures was among the organizations to invest in the round. Statement 

> Mereo BioPharma received a $3 million equity investment. The U.S. investor bought the stock at a 20% discount to Mereo’s closing price the day before the deal was disclosed. Release 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

> DuPont Nutrition & Biosciences entered into a collaboration with MRM Health. The collaborators will combine DuPont’s strains with MRM’s technology to create microbiome-based therapeutics. Statement 

> A Parkinson’s disease collaboration between Servier and Oncodesign passed its first milestone. The event triggered a €1 million milestone payment from Servier. Release 

> The U.K. government made Pfizer’s old Sandwich campus one of six Life Science Opportunity Zones. Government officials will work with the zones to attract investment. Statement 

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.